Skip to main content

Table 2 Criteria for recipient (patient) enrollment

From: Cellular immunotherapy for refractory hematological malignancies

Recipient eligibility criteria  
Inclusion Criteria Age ≥ 18
  Histologic confirmation of the following leukemias/lymphomas:
• Mantle cell lymphoma with Ki-67>30%
• Diffuse Large Cell Lymphoma
• Burkitts Lymphoma
• Systemic T Cell Lymphomas
• Acute Myeloid Leukemia
• Acute Lymphoblastic Leukemia
  Recurrence or progression of disease after at least 1 prior standard treatment
  Progression of disease within 6 months of last treatment
  No available curative treatment option
  ≥ 4-weeks since prior chemotherapy or radiation (Exception: Hydroxyurea may be utilized up to 48 hours prior to treatment)
  Life expectancy of 2 months at treatment initiation
  ≥ 6 months post autologous stem cell transplant
  DLCO ≥ 40% with no symptomatic pulmonary disease.
  LVEF ≥ 40% by MUGA or echocardiogram.
  Creatinine ≤ 2.0 mg/dl, Total bilirubin <1.5x the upper limit of normal (ULN), AST < 3x ULN
  Non-pregnant and willing to use appropriate birth control during study period
Exclusion criteria Previous allogeneic stem cell transplant
  Previous purine analog (fludarabine, pentostatin, 2-CDA) or alemtuzumab within 1 year of entering the study
  CML, CLL, multiple myeloma, and indolent lymphoma (follicular lymphoma, marginal zone lymphoma)
  HLA antibodies to donor HLA type
  HIV-1 or 2 positive
  Oxygen dependant COPD
  Failure to demonstrate adequate compliance with medical therapy and follow-up
  Significant medical or psychiatric illness that would impair the ability to participate in protocol therapy
  Active systemic infection